Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 2 mg | In stock | $ 87 | |
| 4 mg | In stock | $ 156 | |
| 8 mg | In stock | $ 218 | |
| 20 mg | In stock | $ 468 | |
| 40 mg | In stock | $ 748 |
| Description | Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM). |
| Targets&IC50 | TRK: 2-20 nM |
| In vivo | Mice were maintained under aseptic conditions. The care and treatment of experimental animals was in accordance with institutional guidelines. 5 × 10^5 KM12 cells were injected subcutaneously into the dorsal flank area of the mice. Tumor volume was monitored by direct measurement with calipers and calculated by the formula: length × (width^2)/2. Following the establishment of tumor and when the tumor size was between 150–200 mm^2, mice were randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib(LOXO-101). LOXO-101 was administered by oral gavage once daily for 14 days. After the last dose, tissue and blood were collected at 3, 6 and 24 hours post-treatment. |
| Synonyms | LOXO-101, ARRY-470 |
| CAS No. | 1223403-58-4 |
| Chemical Formula | C21H22F2N6O2 |
| Molecular Weight | 428.444 |
| Solubility | DMSO: 4.6 mg/mL (10.74 mM) |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
